CRL Intrinsic Value – James Wilson Encourages Charles River Shareholders With Losses Exceeding $100K To Contact Him Directly
July 9, 2023
☀️Trending News
Charles River Laboratories ($NYSE:CRL) International Inc. is a leading global provider of preclinical and clinical services to the pharmaceutical, medical device and biotechnology industries. The company’s extensive range of services and market presence make it an attractive option for many investors, yet the company has been in a state of disarray of late. James Wilson, Partner in Securities Litigation, is encouraging investors who have suffered losses of more than $100,000 due to their investments with Charles River Laboratories International Inc. to contact him directly. Wilson aims to help those who have invested in Charles River Laboratories International Inc. and have seen their investments diminish in value. He is offering his expertise in securities litigation to assist those in need. His goal is to provide investors with justice and to hold the company accountable if they have breached their fiduciary duties or if they have misled shareholders through false and/or misleading statements.
He is encouraging all shareholders who have suffered losses of more than $100,000 to contact him directly and discuss their specific situation. Wilson is committed to helping investors understand their rights and take action against wrong doings. He is dedicated to fighting for the rights of shareholders and getting them the justice they deserve. By speaking out and publicly announcing his support for investors, Wilson hopes to encourage other shareholders to come forward and take action if they have suffered such losses.
Share Price
On Monday, CHARLES RIVER LABORATORIES INTERNATIONAL (CRL) stock opened at $209.8 and closed at $208.7, a decrease of 0.8 percent from the prior closing price of $210.2. This was disappointing news for shareholders, many of whom have lost over $100K with the stock’s decline. In light of this, James Wilson, Chairman and CEO of CRL, has encouraged any shareholders with losses exceeding $100K to contact him directly. He is committed to helping them recover their losses and has stated that he will do whatever he can to provide them the support that they need. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for CRL. More…
| Total Revenues | Net Income | Net Margin |
| 4.09k | 496.33 | 12.1% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for CRL. More…
| Operations | Investing | Financing |
| 626.39 | -678.53 | -3.87 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for CRL. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 7.7k | 4.54k | 60.74 |
Key Ratios Snapshot
Some of the financial key ratios for CRL are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 14.5% | 21.3% | 17.8% |
| FCF Margin | ROE | ROA |
| 6.7% | 14.9% | 5.9% |
Analysis – CRL Intrinsic Value
At GoodWhale, we recently performed an analysis on the wellbeing of CHARLES RIVER LABORATORIES INTERNATIONAL. After careful consideration, our proprietary Valuation Line calculated the fair value of CHARLES RIVER LABORATORIES INTERNATIONAL’s share to be around $317.7. Unfortunately, this stock is currently being traded at $208.7, meaning it is undervalued by 34.3%. Therefore, our analysis suggests that this could be a wise investment opportunity. More…
Peers
The global market for contract research services is growing rapidly as more and more companies are outsourcing their research and development needs. This growth is being driven by the increasing costs of R&D, the need for faster timelines, and the desire to tap into the expertise of experienced professionals. As the market expands, so does the competition, and Charles River Laboratories International Inc is up against some stiff competition from the likes of Microba Life Sciences Ltd, IDenta Corp, and Eurofins Scientific SE.
– Microba Life Sciences Ltd ($ASX:MAP)
Denta Corp is a publicly traded company that provides dental products and services. The company has a market capitalization of 1.5 million as of 2022 and a return on equity of -10.42%. The company’s products and services include dental implants, dentures, and other dental prosthetics. Denta Corp also provides dental education and training services. The company was founded in 2006 and is headquartered in New York, New York.
– IDenta Corp ($OTCPK:IDTA)
Eurofins Scientific SE is a global leader in the provision of analytical testing and scientific services. The company has a market capitalization of 13.54 billion as of 2022 and a return on equity of 12.32%. The company provides a range of services including food testing, environmental testing, pharmaceutical testing, and forensics. Eurofins Scientific SE has a network of over 800 laboratories across 47 countries.
Summary
Charles River Laboratories International provides specialized services for preclinical drug development. Investors of the company are encouraged to contact James Wilson, a securities litigation partner, if they have suffered losses exceeding $100,000. The company provides services related to drug safety evaluation, clinical pharmacology services, manufacturing and biologics testing.
Their services also include in vivo and in vitro toxicology, immunology, and efficacy testing for small and large molecules. Charles River Laboratories International is positioned to help both academic and commercial organizations in developing new drugs and treatments.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
